دانلود کتاب راهنمای درمان هدفمند سرطان و ایمونوتراپی

The exponential growth of oncology drug development and personalized/targeted therapy in recent years has presented a challenge to even the most experienced cancer researchers. Many of us struggle to keep up with the hundreds of clinical trials conducted each year. To help with this challenge, we have made major updates in this third edition of our concise handbook. Our goal is to make the results of clinical trials of targeted cancer treatments and immunotherapy more easily accessible to cancer researchers and clinicians. We are very proud of the reception the first and second editions have received from oncologists, medical staff, students, and even patients, and we are excited about the updated and widely expanded content included in this third edition. As medical oncologists conducting clinical trials in large phase I cancer center departments, we have had the privilege of observing oncology drug development from a unique perspective. We work at the intersection between exciting preclinical discoveries and the clinical realities of first-in-human clinical trials. This book was conceived with a broad audience in mind. It is our hope that this book will find use among academic oncologists, community oncologists, lab scientists, pharmacists, nurses, residents, clinical fellows, midlevel providers, postdoctoral fellows, and the numerous other staff who are essential for clinical and translational cancer research. Indeed, some motivated patients or family members may even find this book helpful in their quest to identify the most promising cancer treatments available. We approach this book primarily from the viewpoint of clinician investigators. We have focused on agents for which clinical data are available, either published or publicly presented at a national meeting. We did not have the space in this work to mention the many clinical trials for which results were not yet available at the time these pages were sent to press, and we apologize in advance to anyone who is surprised or offended to discover that their favorite agent was not included. Furthermore, we expect that by the time this work is available for purchase, results of ongoing clinical trials will have become available and could significantly alter various aspects of the therapeutic landscape. Importantly, this collection is a handbook, not a textbook. Our goal was to create a publication that was small enough to fit comfortably into a lab coat pocket so that it may be easily accessible for reference in the clinic. To our knowledge, there is not another book available with the scope of this work in such a concise format. The book is divided into four core sections. Please note that throughout the book we have used color-coding to produce an intuitive organizational framework. For example, in Section 1, Food and Drug Administration (FDA)-approved agents are highlighted in green; in Section 3, we have categorized and color-coded what we call the signaling “families” (mTOR, MAP Kinase, SRC, JAK-STAT, etc.). In Section 4, FDA-approved drugs are still in green, whereas those in early phase are in orange and late-phase development are in blue. To conserve pages, the references have been abbreviated in the print book but appear in full form in the companion ebook.